Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2002

View Archived Issues

Novel calcium receptor modulators and their use described in Aventis patent

Two Shionogi patents describe novel immunosuppressant agents

Merck reports development of inhibitors of p38 kinase

Novel cytokine and T-cell production inhibitors and their use in cancer, arthritis, etc.

KN-62 inhibits MAPK/c-Myc activation and proliferation in human keratinocytes

NO-1886 combined with exercise may prevent development of atherosclerosis in the elderly

The antifungal clotrimazole exhibits neuroprotective effects in vitro

PARP inhibitor GPI-6150 effective in rat model of colitis

Antiamnesic effects of DM-232 demonstrated in mice and rats

Efficacy of IS-741 on spontaneous colitis in transgenic rat model

New inhibitors of malonyl-CoA decarboxylase and their use in heart failure, diabetes, obesity, etc.

Vical updates progress of Leuvectin program

Enrollment completed in DIAMOND and SILVER ALT-711 trials

Extended-spectrum oxazolidinone selected for clinical development

INS-37217, a next-generation P2Y2 agonist with an enhanced duration of action

Phase III data in immunocompromised patient population presented for micafungin

Positive results emerge from pilot trial of SCV-07 in tuberculosis

Polyphenon enters pivotal phase III trial for genital warts

Idec gains license to develop HMN-214

IND cleared for Alzhemed phase II

Orphan drug grant for Endostatin trial

Clinical efficacy and safety of ACH-126443 in HBV demonstrated in phase I/II clinical trial

InterMune and Array BioPharma collaborate on hepatitis drug discovery

Twelve-month data show efficacy of anecortave acetate in wet AMD

Iseganan fails to meet primary endpoint in ulcerative oral mucositis phase III trial

deCODE and Merck & Co. form obesity alliance

Triangle's Coviracil outperforms Zerit in phase III trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...